|
X
|
Albuterol + carvedilol
|
15
|
Diminished bronchodilatory effects of albuterol
|
|
Alprazolam + orphenadrine
|
3
|
Increased CNS depressant effects of orphenadrine
|
|
Clarithromycin + ivabradine
|
3
|
Increased risk of ivabradine toxicity
|
|
enoxaparin + rivaroxaban
|
3
|
Increased risk of bleeding
|
|
Orphenadrine + dimenhydrinate
|
3
|
Increased potential for CNS depression
|
|
tramadol + nalbuphine
|
3
|
May diminish the analgesic effect of tramadol
|
|
D
|
Aspirin + enoxaparin
|
229
|
Increased risk of bleeding
|
|
Clopidogrel + enoxaparin
|
214
|
Increased risk of bleeding
|
|
Clopidogrel + omeprazole
|
94
|
Decreased clopidogrel effectiveness and therapeutic failure
|
|
Clopidogrel + esomeprazole
|
6
|
Decreased clopidogrel effectiveness and therapeutic failure
|
|
Aspirin + rivaroxaban
|
6
|
Increased risk of bleeding
|
|
Insulin + sitagliptin
|
6
|
Increased risk of hypoglycemia
|
|
Atorvastatin + diltiazem
|
3
|
Increased risk of myositis, rhabdomyolysis and hepatotoxicity
|
|
Atorvastatin + clarithromycin
|
3
|
Increased serum concentration of atorvastatin may lead to rhabdomyolysis
|
|
Clarithromycin + verapamil
|
3
|
Decreased metabolism and increased therapeutic effects of verapamil
|
|
Warfarin + amiodarone
|
3
|
Increased risk of bleeding
|
|
Warfarin + meloxicam
|
3
|
Increased risk of bleeding
|
|
Digoxin + amiodarone
|
3
|
Increased concentration of digoxin and possible toxicity
|
|
Domperidone + escitalopram
|
3
|
Increased risk of QT interval prolongation
|
|
Furosemide + meloxicam
|
3
|
May decrease the diuretic effect of furosemide
|
|
Tramadol + dimenhydrinate
|
3
|
Increased CNS depressant effect of tramadol
|
